Liver cancer death rate rising: study

SBS News, 9/4/19

The rate of liver cancer deaths and diagnoses has increased substantially in the past three decades, yet researchers say little has been done to help Australians most at risk.

While it is considered a relatively rare type of cancer – nearly 2000 people were diagnosed in 2014 – the high mortality rate and increasing incidence of diagnosis has been concerning, researcher Barbara de Graaff says.

Rates were highest in the Northern Territory, mostly due to a higher prevalence of hepatitis B and C.

Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in PWID

Drug and Alcohol Findings (UK), 2019

What would happen to rates of infection with hepatitis C if we closed down all the needle exchanges? Research has established that needle/syringe programmes are a cost-effective way to reduce spread of HIV, but just two studies have considered the same issue in relation to hepatitis C.

In three UK municipalities, the answers were predicted to be more infections, lost low-cost opportunities to improve and save lives, and in two of the areas, greater health-related costs overall. Conclusion was that these services are among the best investments UK health services can make.

New online learning from ASHM tackles stigma and discrimination in healthcare

The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 1 st March 2019

To mark Zero Discrimination Day, today ASHM has launched Removing Barriers, a new online learning tool for addressing stigma and discrimination in healthcare settings against people affected by HIV, hepatitis B or hepatitis C. 

The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) received funding from the Australian Government Department of Health to address systemic barriers and stigma and discrimination to increase access to the health system by people at risk of or with hepatitis B, hepatitis C or HIV.

“Removing Barriers makes it everybody’s business to change what we say, change what we do and work together in removing the unacceptable barriers of stigma and discrimination across the health system.”

Surveillance of sexually transmitted infections and blood-borne viruses in South Australia, 2017

Communicable Disease Control Branch, SA Health, 2018

In 2017, there were 8,181 new notifications of STIs and BBVs in South Australia. This figure represents a 7% increase in the number of new notifications compared to notifications received in 2016, and a 14% increase compared to the five year average (2012-2016).

In 2017, there were 5,910 notifications of genital chlamydia making this the most commonly notified STI in South Australia.  The notification rate of chlamydia in 2017 was 343 per 100,000 population, and has been stable over the past five years.

There were no notifications of donovanosis in 2017.

There were 1,271 notifications of gonorrhoea in 2017. The notification rate of gonorrhoea increased from 45 per 100,000 population in 2014 to 74 per 100,000 population in 2017.

There were 158 notifications of infectious syphilis in 2017, the highest number of annual notifications in the past 10 years.

There were 60 new diagnoses of HIV infection in 2017. The notification rate of newly diagnosed HIV infection in 2017 was 3.5 per 100,000 population, above that in 2016 of 3.1 per 100,000 population. The notification rate in the Aboriginal population rose to 9.6 per 100,000 in 2017, up from 4.8 per 100,000 in 2016.

There were 11 notifications of newly acquired hepatitis B infection in 2017, above the five year average (2012-2016) of nine cases per year. There were 272 notifications of unspecified hepatitis B virus infection reported in 2017. The notification rate has declined in the Aboriginal population over the past five years.

There were 32 notifications of newly acquired hepatitis C in 2017. The majority of cases were males (75%). The notification rate of unspecified hepatitis C infection was 23 per 100,000 population in 2017.

There were 10 new diagnoses of hepatitis D infection in 2017, which is consistent with the five year average of 10 notifications per year.

 

 

 

 

Hepatitis C – Peer insights on barriers and motivators to Direct-Acting Antiviral (DAA) treatment uptake

ARCSHS, 2018

The knowledge and experience of people who inject drugs (PWID) within peer programs is a vital asset to strategies for the scale-up of DAA treatment among PWID (Brown and Reeders, 2016). This study is focused on translating these “real time” peer insights into resources that support policy and programs to tailor to the needs of communities of people who inject.

This tailoring is critical to achieving the goal of eliminating hepatitis C. This broadsheet is the first of a series that will be produced over the duration of the project. This series will present current peer insights from the peer workers and other members of the people who inject community on the access to and uptake of the new hepatitis C treatment.

This broadsheet provides background to the study and presents an overview of the attitudes, beliefs and experiences of PWID related to the access and scale-up of direct acting antiviral treatment among this community.

A research project by the Australian Research Centre in Sex, Health and Society in collaboration with peer-based organisations – Peer Based Harm Reduction WA, NSW Users and AIDS Association and Harm Reduction Victoria.

Hepatitis C Virus – for GPs, Nurses and Allied Health Professionals

Sonder, October 2018

In this education session, presenters Dr Dep Huynh, Ms Margery Milner and Mr Jeff Stewart will provide attendees with an update on the risk factors associated with Hepatitis C Virus (HCV) and the management options available.

The presenters will also provide information on liver cirrhosis tests and how to choose and initiate the most appropriate HCV treatment for patients.

Learning objectives

  • Identify and understand the risk factors for HCV screening;
  • Perform correct diagnosis of chronic HCV using reflexive testing;
  • Assess and manage patients for liver cirrhosis using non-invasive tests;
  • Improve patient safety by choosing the most appropriate HCV treatment according to the patient’s characteristics and co-medications;
  • Discuss and improve your understanding on how to initiate HCV treatment.

Presented by

Dr Dep Huynh, Gastroentrologist & Staff Specialist at Queen Elizabeth Hospital,
Clinical Lecturer, University of South Australia

Margery Milner & Jeff Stewart, Nurses at Queen Elizabeth Hospital

Agenda

6.30pm – 7.00pm Registration and dinner
7.00pm – 8.00pm Presentation by Dr Dep Huynh, Gastroentrologist & Staff Specialist at Queen Elizabeth Hospital, Clinical Lecturer, University of South Australia8.00pm – 8.10pm Tea/coffee break
8.10pm – 9.10pm Presentation by Margery Milner & Jeff Stewart, Nurses at Queen Elizabeth Hospital
9.10pm – 9.30pm Questions, evaluation & close

RACGP QI & CPD Category 2, 4 Points

DATE AND TIME

Mon. 5 November 2018

6:15 pm – 9:30 pm ACDT

LOCATION

Arya Restaurant

30/81 O’Connell Street

North Adelaide, SA 5006

This program is funded by the Adelaide Primary Health Network - an Australian Government initiative